| Literature DB >> 30827936 |
Eric M Rosenberg1, Reed E S Harrison2, Lun Kelvin Tsou3, Natalie Drucker1, Brock Humphries4, Deepa Rajasekaran1, Kathryn E Luker4, Chien-Huang Wu3, Jen-Shin Song3, Chuan-Jen Wang1, James W Murphy1, Yung-Chi Cheng1, Kak-Shan Shia3, Gary D Luker4, Dimitrios Morikis2, Elias J Lolis5.
Abstract
The G protein-coupled receptor (GPCR) CXCR4 is a co-receptor for HIV and is involved in cancers and autoimmune diseases. We characterized five purine or quinazoline core polyamine pharmacophores used for targeting CXCR4 dysregulation in diseases. All were neutral antagonists for wild-type CXCR4 and two were biased antagonists with effects on β-arrestin-2 only at high concentrations. These compounds displayed various activities for a constitutively active mutant (CAM). We use the IT1t-CXCR4 crystal structure and molecular dynamics (MD) simulations to develop two hypotheses for the activation of the N1193.35A CAM. The N1193.35A mutation facilitates increased coupling of TM helices III and VI. IT1t deactivates the CAM by disrupting the coupling between TM helices III and VI, mediated primarily by residue F872.53. Mutants of F872.53 in N1193.35A CXCR4 precluded constitutive signaling and prevented inverse agonism. This work characterizes CXCR4 ligands and provides a mechanism for N1193.35A constitutive activation.Entities:
Keywords: CXCL12; CXCR4; G protein-coupled receptor (GPCR); constitutively active mutant (CAM); molecular dynamics (MD); small molecule ligands
Mesh:
Substances:
Year: 2019 PMID: 30827936 PMCID: PMC6736600 DOI: 10.1016/j.chembiol.2019.01.012
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116